Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
937 Results for "
peripheral restriction
" in MedChemExpress (MCE) Product Catalog:
Products (937)
937 Results for "peripheral restriction" in MCE Product Catalog:
Cat. No.: HY-P1248
CAS No.: 99566-27-5
Synonyms: NPFF
Target:
Research Areas:
Cat. No.: HY-108652R
CAS No.: 1343364-54-4
Target:
Research Areas:
α,β-Methylene-ATP trisodium (Standard) is the analytical standard of α,β-Methylene-ATP (trisodium) (HY-108652). This product is intended for research and analytical applications. α,β-Methylene-ATP trisodium is an agonist of P2X1 and P2X3 receptors and can cross the blood-brain barrier. α,β-Methylene-ATP trisodium can trigger a reflex pressor response by activating P2X receptors in peripheral muscles and the central locus coeruleus (LC); this effect can be blocked by the P2X antagonist PPADS (HY-108960). α,β-Methylene-ATP trisodium also activates noradrenergic neurons in the central locus coeruleus, mediating antinociceptive effects; this effect can be attenuated by the locus coeruleus damaging agent DSP-4 (HY-103210/HY-121602). α,β-Methylene-ATP trisodium can be used to study the pathological mechanisms of neuropathic pain, cardiovascular reflex regulation, and antinociceptive effects of the central nervous system .
1,2-Didocosahexaenoyl-sn-glycero-3-phosphocholine is a polyunsaturated phospholipid that serves as a component of lipid monolayers and small unilamellar vesicles. 1,2-Didocosahexaenoyl-sn-glycero-3-phosphocholine can be used to prepare endoplasmic reticulum-targeted liposomes (PERLs), which are composed of 1,2-didocosahexaenoyl-sn-glycero-3-phosphoethanolamine, l-α-phosphatidylinositol and l-α-phosphatidylserine at a molar ratio of 1.5:1.5:1:1. PERLs reduce cholesterol levels in human peripheral blood mononuclear cells (PBMCs) and decrease HIV-1 particle secretion from HIV-1-infected PBMCs. Liposomes formed from 1,2-Didocosahexaenoyl-sn-glycero-3-phosphocholine exhibit cytotoxicity against leukemia cells. 1,2-Didocosahexaenoyl-sn-glycero-3-phosphocholine is applicable to studies related to hepatitis C virus infection, HIV infection, hepatitis B virus infection and leukemia .
Cat. No.: HY-168384
CAS No.: 875158-73-9
Target:
Research Areas:
M04 is an agonist of STING. It induces the expression of the IFN reporter gene in HEK293T cells expressing wild-type human STING, but does not induce this expression in HEK293T cells expressing the R71H-G230A-R293Q (HAQ) STING variant or in mouse RAW 264.7 cells, indicating that its activity is dependent on allelic and species variations. M04 induces the production of TNF-α, IL-10, IL-1β, and IL-12p70 in human peripheral blood mononuclear cells (PBMCs). At a concentration of 50 µM, M04 stimulates dendritic cells isolated from PBMCs to express the MHC class II cell surface receptor HLA-DR and co-stimulatory molecules CD40, CD80, and CD86, and also enhances their ability to activate T cells in an ex vivo assay. M04 can be used in research on inflammatory immune diseases .
Cat. No.: HY-177300
CAS No.: 1402802-45-2
Research Areas:
TLR7/8 agonist 13 is an orally active dual agonist of TLR7 (lowest effective concentrations (LEC) [hTLR7] = 1.6 μM) and TLR8 (LEC [hTLR8] = 1.6 μM). TLR7/8 agonist 13 exhibits agonistic activity against human peripheral blood mononuclear cells (hPBMCs) (LEC [hPBMC] = 0.5 μM). TLR7/8 agonist 13 induces endogenous IFNα, activating myeloid dendritic cells and monocytes toward a TH1 phenotype in mice and cynomolgus monkeys. TLR7/8 agonist 13 reduces viral load and HBV surface antigen expression in a mouse model of chronic AAV-HBV infection. TLR7/8 agonist 13 has the potential to indirectly induce IFNγ, which may promote HBV antigen-specific CD8 T cell-mediated responses. TLR7/8 agonist 13 can be used to study hepatitis B virus .
Cat. No.: HY-187014
CAS No.: 141360-03-4
Target:
Research Areas:
NNC 09-0026 is a neuronal calcium channel inhibitor. NNC 09-0026 exhibits IC50 values of 10 μM and 13 μM against neuronal L-type voltage-gated calcium channels, and an IC50 value of 13 μM against rat neuronal N-type voltage-gated calcium channels, with higher selectivity for neuronal L-type channels over peripheral L-type channels. NNC 09-0026 inhibits voltage-dependent Ca 2+ channel currents, blocks Ca 2+ influx through neuronal L-type and N-type voltage-gated calcium channels, and reduces potassium-stimulated calcium uptake in rat cerebral cortex synaptosomes. NNC 09-0026 inhibits TTX-sensitive Na + channel currents in rat cerebellar Purkinje neurons. NNC 09-0026 attenuates ischemia-induced neuronal death, infarct volume and neurological deficits in rat models of cerebral ischemia. NNC 09-0026 can be used for studies on global cerebral ischemia, focal ischemia and cerebral ischemia-related research .
Cat. No.: HY-N8693
CAS No.: 362472-81-9
Category:
Cat. No.: HY-13443S
Synonyms: Exenatide (Leu-13C6,15N) TFA
Exendin-4 (Leu- 13C6, 15N) TFA (Exenatide (Leu- 13C6, 15N) TFA) is the 13C, 15N-labeled Exendin-4 (HY-13443). Exendin‑4 (Exenatide) is an orally active, blood-brain barrier-permeable glucagon-like peptide-1 receptor (GLP‑1 receptor) agonist that resists degradation mediated by dipeptidyl peptidase IV. Exendin‑4 mediates multiple glucose-regulating effects, including stimulation of glucose-dependent insulin secretion, inhibition of glucagon production, increase in β-cell mass, delay of gastric emptying, reduction of food intake, improvement of peripheral insulin sensitivity, and restoration of normal islet structure. Exendin‑4 inhibits oxidative stress, alleviates inflammatory responses, and reduces neuronal apoptosis. Exendin‑4 reduces the aggregation level of mutant huntingtin, improves motor function, prolongs survival time, and regulates the expression levels of leptin and ghrelin. Exendin‑4 can be used in research related to type 2 diabetes, acute ischemic stroke, and Huntington's disease .
Research Areas:
Neurological Disease Metabolic Disease Inflammation/Immunology
NYX-2925 is an orally active, blood-brain barrier-permeable NMDAR modulator, with EC50 values of 55 pM, 28 fM, 11 pM and 55 pM against NR2A, NR2B, NR2C and NR2D, respectively . NYX-2925 enhances synaptic plasticity, long-term potentiation, metaplasticity, structural plasticity, learning ability, memory capacity and circadian rhythm amplitude. NYX-2925 regulates the signaling pathways of Src kinase, EIF2, mTOR, CDK5 and protein kinase A (PKA). NYX-2925 increases the levels of PSD-95, GluA1, activated Src and synaptic GluN2B . NYX-2925 is used in the research of neuropathic pain, fibromyalgia, painful diabetic peripheral neuropathy, post-traumatic stress disorder, cognitive impairment, depression, age-related cognitive decline and NMDAR-mediated central nervous system diseases .
Cat. No.: HY-137055
CAS No.: 1171824-96-6
PF-3774076 is a highly central nervous system (CNS) penetrant, potent, and selective human α1A-adrenoceptor partial agonist. It exhibits good potency and selectivity in multiple binding and functional assays. PF-3774076 increases peak urethral pressure in anesthetized female dogs in a dose-dependent manner via a central mechanism. PF-3774076 affects both the proximal and distal portions of the urethra in vivo. These properties suggest that PF-3774076 may have significant benefit in the treatment of stress urinary incontinence (SUI) as a CNS-penetrant α1A receptor partial agonist. However, despite its partial agonism and selectivity for α1A receptors, PF-3774076 failed to provide adequate safety differences in in vivo models of cardiovascular function. This may be due to the simultaneous activation of both peripheral and central α1A receptors. These data suggest that while central α1A partial agonists may have significant benefit in the treatment of SUI, this class of agents may have difficulty achieving the desired urethral selectivity without affecting cardiovascular function.
Cat. No.: HY-145473S
Synonyms: 15(S)-HETE-SAPE; 15(S)-Hydroxyeicosatetraenoic acid-SAPE-d11; 1-Stearoyl-2-15(S)-HETE-sn-glycero-3-Phosphatidylethanolamine-d11
Cat. No.: HY-119820
CAS No.: 135354-02-8
Synonyms: SR57746A free base
Target:
Akt Dopamine Receptor Trk Receptor 5-HT Receptor PKC JNK ERK
Research Areas:
Xaliproden (SR57746) free base is an orally active, highly selective 5-HT1A receptor agonist. Xaliproden free base activates pertussis toxin-sensitive G protein-coupled signaling cascades, as well as the PKC, ERK1/ERK2, Akt and p21 Ras/MEK-1 pathways. Xaliproden free base also downregulates the JNK/p66/c-Jun signaling pathway, induces phosphorylation of the shc adaptor protein, regulates extracellular dopamine and 5-HT levels, and induces [ 35S]GTPγS labeling in rat brain structures rich in 5-HT1A receptors. Xaliproden free base exerts neurotrophic, neuroprotective, renoprotective, anti-inflammatory, anti-apoptotic, anti-fibrotic and analgesic effects. Xaliproden free base also enhances NGF-induced neurite outgrowth, promotes motor neuron survival, attenuates renal tubular injury and inhibits chemotherapy-induced mechanical allodynia, without activating or altering NGF-induced TrkA receptor activation. Xaliproden free base can be used in the research of motor neuron disease, diabetic nephropathy, chemotherapy-induced peripheral neuropathy, amyotrophic lateral sclerosis, Alzheimer's disease, acute tonic nociceptive pain, inflammatory pain, depression and anxiety .
Cat. No.: HY-P992056
Cat. No.: HY-14604R
CAS No.: 90494-79-4
Synonyms: SR57746A (Standard); SR57746 hydrochloride (Standard)
Research Areas:
Xaliproden (hydrochloride) (Standard) is the analytical standard of Xaliproden (hydrochloride). This product is intended for research and analytical applications. Xaliproden (SR57746) hydrochloride (SR57746A) is an orally active, highly selective 5-HT1A receptor agonist. Xaliproden hydrochloride activates pertussis toxin-sensitive G protein-coupled signaling cascades, as well as the PKC, ERK1/ERK2, Akt and p21 Ras/MEK-1 pathways. Xaliproden hydrochloride also downregulates the JNK/p66/c-Jun signaling pathway, induces phosphorylation of the shc adaptor protein, regulates extracellular dopamine and 5-HT levels, and induces [ 35S]GTPγS labeling in rat brain structures rich in 5-HT1A receptors. Xaliproden hydrochloride exerts neurotrophic, neuroprotective, renoprotective, anti-inflammatory, anti-apoptotic, anti-fibrotic and analgesic effects. Xaliproden hydrochloride also enhances NGF-induced neurite outgrowth, promotes motor neuron survival, attenuates renal tubular injury and inhibits chemotherapy-induced mechanical allodynia, without activating or altering NGF-induced TrkA receptor activation. Xaliproden hydrochloride can be used in the research of motor neuron disease, diabetic nephropathy, chemotherapy-induced peripheral neuropathy, amyotrophic lateral sclerosis, Alzheimer's disease, acute tonic nociceptive pain, inflammatory pain, depression and anxiety .
Cat. No.: HY-118830S
Synonyms: DK-PGD2-d4; 15-Oxo-13,14-dihydro-PGD2-d4; 13,14-Dihydro-15-keto-PGD2-d4
Research Areas:
13,14-Dihydro-15-keto prostaglandin D2-d4 (DK-PGD2-d4; 15-Oxo-13,14-dihydro-PGD2-d4; 13,14-Dihydro-15-keto-PGD2-d4) is the deuterated-labeled 13,14-Dihydro-15-keto prostaglandin D2 (HY-118830). 13,14-Dihydro-15-keto prostaglandin D2 (DK-PGD2; 15-Oxo-13,14-dihydro-PGD2; 13,14-Dihydro-15-keto-PGD2) is a metabolite of Prostaglandin D2 (HY-101988) and acts as a CRTH2 agonist. 13,14-Dihydro-15-keto-prostaglandin D2 exhibits binding activity to CRTH2, induces cellular calcium signaling flux, and mediates eosinophilia in vivo. 13,14-Dihydro-15-keto-prostaglandin D2 activates the CRTH2 receptor, triggering Gi-dependent intracellular calcium mobilization and promoting the migration and recruitment of leukocytes from bone marrow to peripheral blood in vivo. 13,14-Dihydro-15-keto prostaglandin D2 is used in research on inflammation-related diseases, such as bronchial asthma .
Cat. No.: HY-118830S1
CAS No.: 2738376-77-5
Synonyms: DK-PGD2-d9; 15-Oxo-13,14-dihydro-PGD2-d9; 13,14-Dihydro-15-keto-PGD2-d9
Research Areas:
13,14-Dihydro-15-keto prostaglandin D2-d9 (DK-PGD2-d9; 15-Oxo-13,14-dihydro-PGD2-d9; 13,14-Dihydro-15-keto-PGD2-d9) is the deuterated-labeled 13,14-Dihydro-15-keto prostaglandin D2 (HY-118830). 13,14-Dihydro-15-keto prostaglandin D2 (DK-PGD2; 15-Oxo-13,14-dihydro-PGD2; 13,14-Dihydro-15-keto-PGD2) is a metabolite of Prostaglandin D2 (HY-101988) and acts as a CRTH2 agonist. 13,14-Dihydro-15-keto-prostaglandin D2 exhibits binding activity to CRTH2, induces cellular calcium signaling flux, and mediates eosinophilia in vivo. 13,14-Dihydro-15-keto-prostaglandin D2 activates the CRTH2 receptor, triggering Gi-dependent intracellular calcium mobilization and promoting the migration and recruitment of leukocytes from bone marrow to peripheral blood in vivo. 13,14-Dihydro-15-keto prostaglandin D2 is used in research on inflammation-related diseases, such as bronchial asthma .
Cat. No.: HY-P86799
Synonyms: CAGH39 antibody; Caki antibody; Calcium/calmodulin dependent serine protein kinase antibody; Calcium/calmodulin dependent serine protein kinase (MAGUK family) antibody; Calcium/calmodulin dependent serine protein kinase membrane associated guanylate kinase antibody; Calcium/calmodulin-dependent serine protein kinase antibody; CAMGUK antibody; CAMGUK protein antibody; CAMGUK, drosophila, homolog of antibody; casK antibody; CAGH39 antibody; Caki antibody; Calcium/calmodulin dependent serine protein kinase antibody; Calcium/calmodulin dependent serine protein kinase (MAGUK family) antibody; Calcium/calmodulin dependent serine protein kinase membrane associated guanylate kinase antibody; Calcium/calmodulin-dependent serine protein kinase antibody; CAMGUK antibody; CAMGUK protein antibody; CAMGUK, drosophila, homolog of antibody; casK antibody; CMG antibody; CSKP_HUMAN antibody; DXPri1 antibody; DXRib1 antibody; FGS4 antibody; FLJ22219 antibody; FLJ31914 antibody; hCASK antibody; LIN 2 antibody; Lin 2 homolog antibody; LIN2 antibody; Lin2 homolog antibody; MICPCH antibody; MRXSNA antibody; Pals3 antibody; peripheral plasma membrane protein CASK antibody; Protein lin-2 homolog antibody; TNRC8 antibody; Trinucleotide repeat containing 8 antibody; Vertebtate LIN2 homolog antibody;
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
